Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma - Quiz - MDSpire

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • By

  • Martin Zarba

  • Eddy Saad

  • Karl Semaan

  • Talal El Zarif

  • Evan Ferrier

  • Connor Wells

  • Razane El Hajj Chehade

  • Naveen S. Basappa

  • Hedyeh Ebrahimi

  • Mahrukh Huseni

  • Romain Banchereau

  • Rana R. McKay

  • Lori Wood

  • Benoit Beuselinck

  • Cristina Suárez

  • Kosuke Takemura

  • Aly-Khan A. Lalani

  • Haoran Li

  • Lavinia Anne Spain

  • Arnoud J. Templeton

  • Thomas B. Powles

  • Georg A. Bjarnason

  • Guillermo de Velasco

  • Toni K. Choueiri

  • Daniel Y. C. Heng

  • April 15, 2026

  • 0 min

Share

Original Source(s)

Validation of Clinical and Molecular Characteristics of the Highly Favorable IMDC Risk Category in Metastatic Renal Cell Carcinoma

  • by Martin Zarba, Eddy Saad, Karl Semaan, Talal El Zarif, Evan Ferrier, Connor Wells, Razane El Hajj Chehade, Naveen S. Basappa, Hedyeh Ebrahimi, Mahrukh Huseni, Romain Banchereau, Rana R. McKay, Lori Wood, Benoit Beuselinck, Cristina Suárez, Kosuke Takemura, Aly-Khan A. Lalani, Haoran Li, Lavinia Anne Spain, Arnoud J. Templeton, Thomas B. Powles, Georg A. Bjarnason, Guillermo de Velasco, Toni K. Choueiri, Daniel Y. C. Heng

  • April 15, 2026

Related Content

Renal arterial pseudoaneurysm after robotic-assisted partial nephrectomy: a single-center analysis

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC

Marc Machaalani, MD on MAdCAM-1

Kidney cancer research at ESMO25: Dana-Farber's Marc Machaalani, MD, shares 3 key takeaways from his presentation on the protein MAdCAM-1 and its ability to predict outcomes in patients with metastatic renal cell carcinoma.

  • November 5, 2025

  • 1 min